bmy 25067 has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ganesan, TS; Green, JA; Harris, AL; LaCreta, FP; Macaulay, VM; McKinley, L; O'Byrne, KJ; Philip, PA; Talbot, DC; Winograd, B | 1 |
| de Boer-Dennert, M; Planting, AS; Schellens, JH; Stoter, G; van der Burg, ME; Verweij, J; Winograd, B | 1 |
2 trial(s) available for bmy 25067 and Neoplasms
| Article | Year |
|---|---|
Phase I study of the mitomycin C analogue BMS-181174.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Female; Heart; Humans; Kidney; Lung; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasms; Thrombophlebitis | 1998 |
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Area Under Curve; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Infusions, Intravenous; Male; Middle Aged; Mitomycin; Mitomycins; Neoplasm Staging; Neoplasms; Vascular Diseases | 1999 |